Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

407 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of denosumab for restoring normal bone mineral density in women receiving adjuvant aromatase inhibitors for early breast cancer.
Sakaguchi K, Ono H, Nakatsukasa K, Ishikawa T, Hasegawa Y, Takahashi M, Niikura N, Koizumi K, Sakurai T, Shigematsu H, Takahashi S, Taira S, Suzuki M, Narui K, Miura D, Yamada K, Yoshimura M, Shioya H, Konishi E, Isao Y, Imai K, Fujikawa K, Taguchi T; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Sakaguchi K, et al. Among authors: konishi e. Medicine (Baltimore). 2019 Aug;98(32):e16770. doi: 10.1097/MD.0000000000016770. Medicine (Baltimore). 2019. PMID: 31393399 Free PMC article. Clinical Trial.
Myoid hamartoma of the breast that proved difficult to diagnose: a case report.
Mizuta N, Sakaguchi K, Mizuta M, Imai A, Nakatsukasa K, Morita M, Soshi M, Goto M, Yasukawa S, Konishi E, Taguchi T. Mizuta N, et al. Among authors: konishi e. World J Surg Oncol. 2012 Jan 16;10:12. doi: 10.1186/1477-7819-10-12. World J Surg Oncol. 2012. PMID: 22248347 Free PMC article.
Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer.
Nakatsukasa K, Koyama H, Oouchi Y, Imanishi S, Mizuta N, Sakaguchi K, Fujita Y, Fujiwara I, Kotani T, Matsuda T, Fukuda K, Morita M, Kawakami S, Kadotani Y, Konishi E, Yanagisawa A, Taguchi T. Nakatsukasa K, et al. Among authors: konishi e. Breast Cancer. 2017 Jan;24(1):63-68. doi: 10.1007/s12282-016-0666-7. Epub 2016 Jan 11. Breast Cancer. 2017. PMID: 26754092 Clinical Trial.
Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer.
Nakatsukasa K, Koyama H, Oouchi Y, Imanishi S, Mizuta N, Sakaguchi K, Fujita Y, Imai A, Okamoto A, Hamaoka A, Soushi M, Fujiwara I, Kotani T, Matsuda T, Fukuda K, Morita M, Kawakami S, Kadotani Y, Konishi E, Yanagisawa A, Goto M, Yamada K, Taguchi T. Nakatsukasa K, et al. Among authors: konishi e. Breast Cancer. 2017 Jan;24(1):92-97. doi: 10.1007/s12282-016-0677-4. Epub 2016 Feb 13. Breast Cancer. 2017. PMID: 26874836 Clinical Trial.
Effect of denosumab administration on low bone mineral density (T-score -1.0 to -2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer.
Nakatsukasa K, Koyama H, Ouchi Y, Sakaguchi K, Fujita Y, Matsuda T, Kato M, Konishi E, Taguchi T. Nakatsukasa K, et al. Among authors: konishi e. J Bone Miner Metab. 2018 Nov;36(6):716-722. doi: 10.1007/s00774-017-0884-x. Epub 2017 Nov 7. J Bone Miner Metab. 2018. PMID: 29116414 Clinical Trial.
Effect of denosumab on bone mineral density in Japanese women with osteopenia treated with aromatase inhibitors for breast cancer: subgroup analyses of a Phase II study.
Nakatsukasa K, Koyama H, Ouchi Y, Sakaguchi K, Fujita Y, Matsuda T, Kato M, Konishi E, Taguchi T. Nakatsukasa K, et al. Among authors: konishi e. Ther Clin Risk Manag. 2018 Jul 10;14:1213-1218. doi: 10.2147/TCRM.S167579. eCollection 2018. Ther Clin Risk Manag. 2018. PMID: 30022834 Free PMC article.
407 results